News
Press Releases
Posters & Presentations
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
Dr. Duda to apply deep expertise in rare and immune-mediated diseases
Newton, MA & Wädenswil, Switzerland – January 8, 2026
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
Financing led by Novo Holdings with significant support from world-class group of existing and new investors
Newton, MA & Wädenswil, Switzerland – May 27, 2025
GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer
Wadenswil, Switzerland & Boston, Massachusetts USA – January 5, 2024
GlycoEra AG Expands Board of Directors and Appoints Santiago Arroyo, MD as an independent board member
Wadenswil, Switzerland & Boston, Massachusetts USA – May 2, 2023
GlycoEra AG Expands Board of Directors and Appoints Georges Gemayel, Ph.D., as Chair
GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel, Ph.D., as Chair, as well as Philippe Dro, Ph.D., M.B.A., and Kush Parmar, M.D., Ph.D.
Schlieren, Switzerland & Boston, Massachusetts USA – July 12, 2022
GlycoEra AG Announces Appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer
Dr. Ganguly brings nearly 25 years of experience in biopharmaceutical research and development across a variety of therapeutic areas including autoimmune diseases, inflammation, and oncology, among others.
Schlieren, Switzerland & Boston, Massachusetts USA – June 16, 2022
GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer
Dr. Kaundinya has been a member of the GlycoEra AG Board of Directors since the company’s inception in 2020, helping the team define corporate strategy and raise Series A capital of more than $49 million (CHF 45 million).
Schlieren, Switzerland & Boston, Massachusetts USA – May 3, 2022
GlycoEra AG raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform
GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.
Schlieren, Switzerland – November 5, 2021
GlycoEra AG Announces its Incorporation and Welcomes Ganesh Kaundinya as Inaugural Member of the Board of Directors
GlycoEra AG announced today its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications.
Schlieren, Switzerland – January 5, 2021
